We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Allogeneic Umbilical Cord Blood Therapy for Stroke

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01884155
First Posted: June 21, 2013
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
MinYoung Kim, M.D., Bundang CHA Hospital
June 19, 2013
June 21, 2013
October 12, 2017
June 2013
May 2015   (Final data collection date for primary outcome measure)
Changes in Balance [ Time Frame: Baseline - 1 month - 3 months - 6 months - 12 months ]
Same as current
Complete list of historical versions of study NCT01884155 on ClinicalTrials.gov Archive Site
  • Changes in Mobility [ Time Frame: Baseline - 1 month - 3 months - 6 months - 12 months ]
  • Changes in Muscle strength and Spasticity [ Time Frame: Baseline - 1 month - 3 months - 6 months - 12 months ]
  • Changes in Activities of Daily Living [ Time Frame: Baseline - 1 month - 3 months - 6 months - 12 months ]
  • Changes in Function of Upper extremity [ Time Frame: Baseline - 1 month - 3 months - 6 months - 12 months ]
  • Changes in Hand function [ Time Frame: Baseline - 1 month - 3 months - 6 months - 12 months ]
  • Changes in Visual perception [ Time Frame: Baseline - 1 month - 3 months - 6 months - 12 months ]
  • Changes in Cognition [ Time Frame: Baseline - 1 month - 3 months - 6 months - 12 months ]
  • Changes in Language [ Time Frame: Baseline - 1 month - 3 months - 6 months - 12 months ]
  • Changes in Sensory function [ Time Frame: Baseline - 1 month - 3 months - 6 months - 12 months ]
  • Changes in Brain structure [ Time Frame: Baseline - 12 months ]
  • Changes in Brain glucose metabolism [ Time Frame: Baseline - 12 months ]
  • Changes in Neural activity [ Time Frame: Baseline - 6 months - 12 months ]
  • Monitoring Adverse Events [ Time Frame: Baseline - 1 month - 3 months - 6 months - 12 months ]
Same as current
Not Provided
Not Provided
 
Allogeneic Umbilical Cord Blood Therapy for Stroke
Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy for Patients With Stroke
This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood (UCB) therapy for patients with stroke.
Stroke is one of the most common etiologies causing disability in developed countries. There remains no proven treatments except tissue plasminogen activator currently. Based on promising results of cell therapy in animal stroke models, efforts to apply cell therapy for patients with stroke has been made. UCB possess various stem or progenitor cells and is known to secrete neurotrophic factors to repair injured brain. This clinical research aims to determine the safety and efficacy of allogeneic UCB for stroke.
Interventional
Phase 1
Intervention Model: Single Group Assignment
Intervention Model Description:
allogeneic cord blood for stroke patients
Masking: None (Open Label)
Primary Purpose: Treatment
Stroke
Procedure: Allogeneic umbilical cord blood therapy
Experimental: Allogeneic umbilical cord blood therapy
Allogeneic umbilical cord blood therapy
Intervention: Procedure: Allogeneic umbilical cord blood therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5
December 2015
May 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ischemic or hemorrhagic stroke
  • Onset duration over 12 months
  • Hemisphere lesions except brain stem and cerebellar lesions
  • National Institute Health Stroke Scale: 10 to 15

Exclusion Criteria:

  • Possibility of hypersensitivity drugs used in this study
  • Uncontrolled hypertension or cardiovascualr diseases
  • Malignant cancer
  • Renal or hepatic dysfunction (Consultation to specialist in nephrology or gastroenterology in case of renal or hepatic dysfunction)
  • Severe pulmonary dysfunction
  • Traumatic brain injury
  • Lack of matched UCB
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT01884155
UCBStroke
No
Not Provided
Not Provided
MinYoung Kim, M.D., Bundang CHA Hospital
MinYoung Kim, M.D.
Not Provided
Principal Investigator: MinYoung Kim, M.D., Ph.D. CHA University
Bundang CHA Hospital
October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP